Challenges in understanding the structure/activity relationship of Aβ oligomers
A major hallmark of Alzheimer’s disease (AD) is the accumulation and deposition of fibrillar aggregates of the amyloid-b (Ab) peptide into neuritic plaques. These amyloid deposits were thought to play a central role in AD; however, the correlation between plaque load and disease is weak. Increasing...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AIMS Press
2019-01-01
|
| Series: | AIMS Biophysics |
| Subjects: | |
| Online Access: | https://www.aimspress.com/article/10.3934/biophy.2019.1.1/fulltext.html |
| _version_ | 1828373687047290880 |
|---|---|
| author | Albert W. Pilkington IV Justin Legleiter |
| author_facet | Albert W. Pilkington IV Justin Legleiter |
| author_sort | Albert W. Pilkington IV |
| collection | DOAJ |
| description | A major hallmark of Alzheimer’s disease (AD) is the accumulation and deposition of fibrillar aggregates of the amyloid-b (Ab) peptide into neuritic plaques. These amyloid deposits were thought to play a central role in AD; however, the correlation between plaque load and disease is weak. Increasing evidence supports the notion that a variety of small, globular aggregates of Ab, referred to broadly as Ab oligomers (AbO), may in fact be the primary culprits associated with neurotoxicity. Evaluation of AbO structure and physiological activity is complicated by their metastability, heterogeneity, complex aggregation pathways, and dependence on experimental conditions. Numerous different types of oligomers have been reported, and these have been associated with varying degrees of toxicity and modes of interaction. Here, we briefly review AbOs with a focus on their formation, structure, and biophysical methods applied to their investigation. |
| first_indexed | 2024-04-14T07:22:45Z |
| format | Article |
| id | doaj.art-93e2b3131df24d849e34a0895f5cb034 |
| institution | Directory Open Access Journal |
| issn | 2377-9098 |
| language | English |
| last_indexed | 2024-04-14T07:22:45Z |
| publishDate | 2019-01-01 |
| publisher | AIMS Press |
| record_format | Article |
| series | AIMS Biophysics |
| spelling | doaj.art-93e2b3131df24d849e34a0895f5cb0342022-12-22T02:06:06ZengAIMS PressAIMS Biophysics2377-90982019-01-016112210.3934/biophy.2019.1.1Challenges in understanding the structure/activity relationship of Aβ oligomersAlbert W. Pilkington IV0Justin Legleiter11 The C. Eugene Bennett Department of Chemistry, West Virginia University, 217 Clark Hall, P.O. Box 6045, Morgantown, West Virginia 26505, United States1 The C. Eugene Bennett Department of Chemistry, West Virginia University, 217 Clark Hall, P.O. Box 6045, Morgantown, West Virginia 26505, United States 2 Blanchette Rockefeller Neurosciences Institutes, West Virginia University, 1 Medical Center Dr., P.O. Box 9303, Morgantown, West Virginia 26505, United States 3 Department of Neuroscience, West Virginia University, 1 Medical Center Dr., P.O. Box 9303, Morgantown, West Virginia 26505, United StatesA major hallmark of Alzheimer’s disease (AD) is the accumulation and deposition of fibrillar aggregates of the amyloid-b (Ab) peptide into neuritic plaques. These amyloid deposits were thought to play a central role in AD; however, the correlation between plaque load and disease is weak. Increasing evidence supports the notion that a variety of small, globular aggregates of Ab, referred to broadly as Ab oligomers (AbO), may in fact be the primary culprits associated with neurotoxicity. Evaluation of AbO structure and physiological activity is complicated by their metastability, heterogeneity, complex aggregation pathways, and dependence on experimental conditions. Numerous different types of oligomers have been reported, and these have been associated with varying degrees of toxicity and modes of interaction. Here, we briefly review AbOs with a focus on their formation, structure, and biophysical methods applied to their investigation.https://www.aimspress.com/article/10.3934/biophy.2019.1.1/fulltext.htmlalzheimer’s diseaseβ-amyloidoligomersneurodegenerationprotein aggregation |
| spellingShingle | Albert W. Pilkington IV Justin Legleiter Challenges in understanding the structure/activity relationship of Aβ oligomers AIMS Biophysics alzheimer’s disease β-amyloid oligomers neurodegeneration protein aggregation |
| title | Challenges in understanding the structure/activity relationship of Aβ oligomers |
| title_full | Challenges in understanding the structure/activity relationship of Aβ oligomers |
| title_fullStr | Challenges in understanding the structure/activity relationship of Aβ oligomers |
| title_full_unstemmed | Challenges in understanding the structure/activity relationship of Aβ oligomers |
| title_short | Challenges in understanding the structure/activity relationship of Aβ oligomers |
| title_sort | challenges in understanding the structure activity relationship of aβ oligomers |
| topic | alzheimer’s disease β-amyloid oligomers neurodegeneration protein aggregation |
| url | https://www.aimspress.com/article/10.3934/biophy.2019.1.1/fulltext.html |
| work_keys_str_mv | AT albertwpilkingtoniv challengesinunderstandingthestructureactivityrelationshipofaboligomers AT justinlegleiter challengesinunderstandingthestructureactivityrelationshipofaboligomers |